Clinical Study of Probiotic Enteral Nutrition to Improve Intestinal Flora and Chemotherapy-related Complications in Gastric Cancer Patients Undergoing Chemotherapy

Abstract

OBJECTIVE: In the treatment of gastric cancer patients undergoing chemotherapy, it is important to investigate the effect of probiotic enteral nutrition not only to improve intestinal flora, but also to improve chemotherapy-related complications. METHODS: From September 2021 to September 2022, 60 patients with gastric cancer combined with nutritional risk who were hospitalized in the Department of Medical Oncology of our hospital were selected and then divided into 3 groups: 1. control group: patients were given dietary guidance while chemotherapy. 2. enteral nutrition group: oral nutrition therapy was given while chemotherapy. 3. combined probiotics group: enteral nutrition combined with probiotics was given while chemotherapy. treatment. For all study subjects, the following study indexes were examined at the time of admission and after chemotherapy: 1. intestinal flora 2. hematological indexes: white blood cells, red blood cells, platelets, blood albumin, prealbumin, T-cell subsets, immunoglobulins, etc. 3. physical indexes: body weight, body composition. 4. symptomatic indexes: stool properties and frequency, severity of nausea and vomiting. RESULTS: From the results, before treatment, there was basically no difference in intestinal flora among the three groups. After treatment, the intestinal flora of patients in the combined probiotic group was relatively low. It can be seen that probiotics can contribute to the reduction of intestinal flora, P<0.05; before treatment, there was basically no difference in the hematological indexes of patients in the three groups. After treatment, the hematological indexes of patients in the combined probiotic group were relatively normal. It can be seen that probiotics can contribute to the normalization of hematological indexes, p<0.05; before treatment, there was basically no difference in either the weight of the patients in the three groups or their body composition. After treatment, the body indexes of patients in the combined probiotic group returned to normal. It can be seen that probiotics can promote the return of body indexes to normal; before treatment, there was basically no difference in the stool properties and frequency, or the severity of nausea and vomiting among the three groups of patients. After treatment, the patients in the combined probiotic group had normalized their symptoms. It can be seen that probiotics can contribute to the normalization of symptom indexes. CONCLUSION: When treating patients with gastric cancer chemotherapy, applying probiotics to them can effectively improve both the number of intestinal flora and hematological indicators, as well as physical indicators and symptom indicators, which in turn can promote patients' remission and recovery from symptoms.